Welcome to the Medrio Monthly News Roundup, in which we brief you on a sample of events and developments taking place around the industry. This recurring update functions on popular demand – the stories in this post come from the articles in our social media feeds that garnered the most attention from our readers and followers. Your likes, clicks, and retweets decide which stories make it beyond your newsfeed and onto our blog.
This week, we bring you growth forecasts for the eClinical solutions market, a check-in on the development of liquid biopsies, and a brief discussion on regulatory changes on the horizon in Europe. Take a look, and tune in for the next roundup in a month!
1. Growth for eClinical in the coming years
Hexa Research has released a report predicting major growth in the eClinical solutions market by 2024. Among the major causes of this growth is the current health of the clinical research industry: R&D and funding are up, both in government and in the private sector, and the consumer base for new drugs is growing. Another cause is the increased adoption of tools like EDC. The market growth is not, however, without its caveats, as high costs and skill requirements may pose limitations, creating a potential advantage for inexpensive, user-friendly EDC solutions.
2. A new approach to liquid biopsies
The quest to develop a liquid biopsy, which would allow doctors to detect an array of cancers from a simple blood draw, has created a great deal of buzz among oncologists and other healthcare professionals. It has also attracted funding from high-profile venture capitalists like Bill Gates and Jeff Bezos, as we reported last year. In December, we shared an article from STAT News profiling the efforts of a pair of Boston scientists who have taken a new approach to developing this innovative – but, so far, elusive – diagnostic capability.
3. The EMA looks to change data reporting requirements
Seeking improvements in the storage and reporting of drug data, new EMA regulations will require any pharma company involved in European markets to change the way they report their Chemistry, Manufacturing, and Controls data. The Xtalks blog recently published a short interview with a European life sciences consultant covering the regulations and what pharma companies will have to do to become compliant by the 2018 deadline. The consultant also discussed the reasons for the regulatory changes, and how exactly they will impact data reporting.
That’s all for this roundup. We’ll have three more stories for you next month. In the meantime, check out this blog every week for new insights into EDC and clinical research.